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CLINICAL INVESTIGATION
Formulation of Buprenorphine for Sublingual Use in Neonates
Ellena A.Anagnostis, PharmD,1 Rania E. Sadaka, PharmD,1 LindaA. Sailor, PharmD,1 David E.Moody, PhD,2 Kevin
C. Dysart, MD,3 andWalter K. Kraft, MD4
1Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, 2University of Utah,
Center for Human Toxicology, Salt Lake City, Utah, 3The Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania; at the time of writing, A.I. DuPont Hospital for Children, Wilmington, Delaware, and 4Department of
Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania
OBJECTIVES The only medication used sublingually in the neonate is buprenorphine for the treatment
of neonatal abstinence syndrome (NAS). Compared with morphine, buprenorphine reduces the length of
treatment and length of hospitalization in neonates treated for NAS. The objective of this study was to
characterize the stability of ethanolic buprenorphine for sublingual administration.
METHODS Buprenorphine solution was prepared and stored in amber glass source bottles at either
688F to 778F (208C-258C) or 368F to 468F (2.28C-7.88C). Samples were collected from each of these
batches on days 0, 3, 7, 14, and 30. Additional samples were withdrawn at baseline from each batch and
placed in oral dispensing syringes for 3 and 7 days. Buprenorphine concentration was assessed by liquid
chromatography–electrospray ionization–tandem mass spectrometry.
RESULTS Neither storage temperature (p¼0.65) nor storage time (p¼0.24) significantly affected
buprenorphine concentrations. All of the mean concentrations, regardless of storage temperature, were
above 95% of the labeled concentration, and the potency was maintained for samples stored either in the
original amber glass source bottles or in oral syringes.
CONCLUSIONS An ethanolic buprenorphine solution is stable at room temperature for 30 days.
INDEX TERMS buprenorphine, drug stability, newborn infant, pharmaceutical chemistry, sublingual
administration
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INTRODUCTION
The cessation of placental transfer of maternally
ingested opioids is associated with signs of with-
drawal in the newborn. This condition, called
neonatal abstinence syndrome (NAS), is associated
with irritability, poor feeding, autonomic dysfunc-
tion, and occasionally seizure. Signiﬁcant heteroge-
neity continues to exist in the diagnosis and
treatment of neonates at risk for opiate withdraw-
al.1,2 Cochrane Reviews,3,4 the American Academy
of Pediatrics,5 and expert review6 identify opioid
replacement as the ideal treatment for the with-
drawal symptoms associated with in utero exposure
to opiates.
The standard of care at Thomas Jefferson
University Hospital is an oral morphine solution
administered every 4 hours. This therapy is
associated with a 4 to 6–week length of hospital-
ization.7 Compared to morphine, investigations
with sublingual buprenorphine as a treatment for
NAS show about a 30% decrease in both the length
of treatment and length of hospitalization.8,9 The
formulation used in these preliminary studies was
buprenorphine 0.3 mg/mL (Buprenex, Reckitt
Benckiser, Richmond, VA) and simple syrup in a
30% ethanolic solution. The use of 30% ethanol
was mandated by the Food and Drug Administra-
tion during initial investigational new drug discus-
sions. After an initial cohort employed a solution of
buprenorphine of 0.06 mg/mL, the concentration
was increased to 0.075 mg/mL. The stock bottle and
individual doses were stored at room temperature
with a 72-hour expiration date. A pharmacokinetic/
pharmacodynamic model-generated bioavailability
estimate of buprenorphine on an individual infant
basis is 12% to 56%,10 a range within the 95%
conﬁdence interval of the 33% value seen in adults
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for an ethanol-based solution.11 The current inves-
tigation was undertaken with a goal of character-
izing the stability of ethanolic buprenorphine for
sublingual administration.
MATERIALS AND METHODS
Two batches of buprenorphine solution were
prepared. One batch was stored at room tempera-
ture, 688F to 778F (208C-258C), while the other was
refrigerated at 368F to 468F (2.28C-7.88C). The pH
of the formulation is 5.4. From each of these
batches, samples were withdrawn from the amber
glass bottle into 1-mL polypropylene tubes on days
0, 3, 7, 14, and 30 and stored at 708C (Figure 1)
until analysis was conducted. Two additional
samples were withdrawn at baseline from an amber
glass bottle and placed into the oral syringes (1-mL
Exacta-Med oral dispensers, item number 172-3733,
Baxa, Englewood, CO) used to dispense the
solution at Thomas Jefferson University Hospital.
On days 3 and 7, the samples from the oral syringes
were transferred to 1-mL polypropylene tubes and
stored in the 708C freezer. Samples were assessed
within 6 months of collection.
Buprenorphine was measured by liquid chroma-
tography–electrospray ionization–tandem mass
spectrometry essentially as described by Moody et
al12 The assay was designed for biological samples,
and the same method of extraction was used in this
study. Buprenorphine-d4 and nobuprenorphine-d3
were added as the internal standards. The limit of
quantiﬁcation was 0.1 ng/mL. Samples were as-
sayed on 2 days within 6 months of collection.
During method validation the intraassay accuracy
(% target)/precision (%CV) at 0.1, 0.25, 1, and 5
ng/mL were 109/6.4, 92/2.6, 102/2, and 94.2/1.1,
respectively. The respective interassay accuracy and
precision were 105/3.8, 92.4/3.5, 103/3.9, and 95.6/
3.6. During the 2 analytical runs for study samples
the mean accuracy and precision at 0.25, 2, and 7.5
ng/mL were 94/19.5, 102/4.4, and 98/2.2, respec-
tively.
Figure 1. Study procedure
All samples were transferred to 1-mL polypropylene tubes either directly from the amber glass source bottle or
from an oral syringe. The tubes were stored at 708 C until sent for stability analysis.
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Each of the 7 samples per batch was assayed 4
times to yield 28 data points for each of the 2
batches of buprenorphine solution. Measured
values were compared using 2-way analysis of
variance to assess the impact of both storage time
and temperature on the buprenorphine concentra-
tion. Statistical analysis was performed with JMP
version 8.0 (SAS Institute, Cary, NC).
RESULTS
Buprenorphine concentrations throughout the
study are shown in Figure 2. No norbuprenorphine
was detected. Neither storage temperature (p¼0.65)
nor storage time (p¼0.24) signiﬁcantly affected
buprenorphine concentration. Of note, all of the
mean concentrations, regardless of storage temper-
ature, were above 95% of the labeled concentration
of 0.075 mg/mL, the threshold established in the
Food and Drug Administration stability testing
guidance for the pharmaceutical industry.13 This
potency was maintained for samples stored either in
the original amber glass source bottles or in oral
syringes until removed and placed in the polypro-
pylene tubes for analysis.
The correlation coefﬁcients (r) for all storage
conditions ranged from 0.032 to 0.23. These results
conﬁrmed that there was no statistically signiﬁcant
relationship between the times when samples were
collected for analysis and the buprenorphine
concentrations (p.0.1), indicating minimal drug
degradation over the study period.
DISCUSSION
While there is variability in diagnosing and
treating neonates at risk for opiate withdrawal,
opioid replacement is considered an ideal treatment
for withdrawal symptoms associated with in utero
exposure to opiates. Sublingual buprenorphine
solution is of interest in the treatment of NAS
because the lengths of hospitalization for neonates
treated with oral morphine solution range from 4 to
6 weeks. An initial comparison of sublingual
buprenorphine with oral morphine solution at
Thomas Jefferson University Hospital for NAS
showed a shorter length of treatment and shorter
length of hospitalization with buprenorphine.
The buprenorphine concentrations from samples
collected on days 3, 7, 14, and 30 showed no
evidence of drug degradation and no apparent
relationship to the time from batch preparation.
Additionally, little difference was found between
concentrations of samples stored at room temper-
ature versus those stored under refrigeration.
Samples also maintain their potency when stored
in oral syringes for up to 7 days. Based on these
results, the expiration dates for buprenorphine
solution have been changed in clinical research at
Thomas Jefferson University Hospital. The solu-
tion stored in glass bottles is given an expiration
date of 30 days at room temperature, and the
solution stored in syringes is given an expiration
date of 7 days at room temperature.
Our study includes certain limitations. The assay
used was developed for analysis of biological
samples; it was not optimized for evaluation of
formulations with single targets of concentrations.12
While multiple samples were obtained and analyzed
for each time point, additional replicate samples
would have strengthened the study design. Addi-
tionally, the samples were stored at temperatures
deﬁned by ranges for room temperature and
refrigeration that would reﬂect practice, rather than
a particular actual temperature. While a baseline
sample was collected from each of the 2 amber glass
source bottles, a separate sample was not obtained
from the oral syringes in which the initial samples
were placed. Therefore, our reported concentration
changes from baseline for the samples stored in oral
syringes represent an approximation rather than
deﬁnitive results.
Based on the results of this study, the 30-day
stability of the formulation should allow for
convenient storage, less pharmaceutical waste, and
decreased cost in future clinical trials of sublingual
buprenorphine used for treatment of NAS.
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Figure 2. Buprenorphine concentration as a function
of time
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